Myoepithelial Tumors of Bone.

Wangzhao Song, Uta Flucke, Albert J H Suurmeijer

Journal: Surgical pathology clinics 2018;10(3):657-674

PMID: 28797507

Full Text on Elsevier Science View on PubMed

Abstract

Myoepithelial tumors (METs) of bone (BMETs) are a rare but distinct tumor entity. METs that are cytologically benign are termed myoepitheliomas; METs with malignant histologic features are called myoepithelial carcinomas. BMETs have a wide age range, may involve any part of the skeleton, and have a variable spindle cell and epithelioid morphology. Bone tumors to be considered in the differential diagnosis are discussed. Additional techniques are indispensable to correctly diagnose BMETs. By immunohistochemistry, BMETs often express cytokeratins and/or EMA together with S100, GFAP, or calponin. Half of BMETs harbor EWSR1 (or rare FUS) gene rearrangements with different gene partners.

Address: Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, PO Box 30.001, Groningen 9700RB, The Netherlands.; Department of Pathology, Nijmegen Medical Center, Radboud University, PO Box 9101, Nijmegen 6500HB, The Netherlands.; Department of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, PO Box 30.001, Groningen 9700RB, The Netherlands. Electronic address: [email protected].

DOI: 10.1016/j.path.2017.04.010